Status:
RECRUITING
Precision Imaging to Evaluate Kaposi Sarcoma
Lead Sponsor:
Washington University School of Medicine
Collaborating Sponsors:
National Cancer Institute (NCI)
Pensievision
Conditions:
Kaposi Sarcoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
AIM 1: In Uganda and Kenya, Kaposi Sarcoma (KS) is one of the most common cancers and a leading cause of cancer-related deaths in men. However, tracking how well patients are responding to treatment ...
Eligibility Criteria
Inclusion
- Inclusion Criteria - Aim 2 (Patients):
- Adults age ≥18 years old
- Histopathology-confirmed Kaposi Sarcoma
- At least 3 skin lesions
- Capable of informed consent
- On treatment for Kaposi Sarcoma
- Exclusion Criteria - Aim 2 (Patients):
- Patients not initiating Kaposi Sarcoma treatment
- Very ill patients requiring hospitalization
- Inclusion Criteria - Aim 3 (Patients):
- Adults age ≥18 years old
- Histopathology-confirmed Kaposi Sarcoma
- Capable of informed consent
- Initiating treatment for Kaposi Sarcoma
- Exclusion Criteria - Aim 3 (Patients):
- Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2
- Prior or ongoing Kaposi Sarcoma treatment
Exclusion
Key Trial Info
Start Date :
March 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2029
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06898203
Start Date
March 28 2025
End Date
November 30 2029
Last Update
July 24 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kenya Medical Research Institute
Kisumu, Kenya
2
Infectious Diseases Institute, Makerere University
Kampala, Uganda